Status:
APPROVED_FOR_MARKETING
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Lead Sponsor:
Janssen Biotech, Inc.
Collaborating Sponsors:
Pharmacyclics LLC.
Conditions:
Relapsed or Refractory Mantle Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to colle...
Eligibility Criteria
Inclusion
- Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible.
Exclusion
- Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible.
- Patients previously treated with ibrutinib are not eligible.
- Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01833039
Last Update
February 3 2025
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States
2
Duarte, California, United States
3
Los Angeles, California, United States
4
Stanford, California, United States